Related Content
Search Google Scholar for:
|
|
Science 12 May 1989: Vol. 244. no. 4905, pp. 707 - 712 DOI: 10.1126/science.2470152
|
|
Articles
Science, Vol 244, Issue 4905, 707-712
Copyright © 1989 by American Association for the Advancement of Science
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
DJ Slamon,
W Godolphin,
LA Jones,
JA Holt,
SG Wong,
DE Keith,
WJ Levin,
SG Stuart,
J Udove,
A Ullrich,
and
al. et
Department of Medicine, U.C.L.A. School of Medicine 90024.
Carcinoma of the breast and ovary account for one-third of all cancers occurring in women and together are responsible for approximately one-quarter of cancer-related deaths in females. The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior. In this report, several similarities were found in the biology of HER-2/neu in breast and ovarian cancer, including a similar incidence of amplification, a direct correlation between amplification and over-expression, evidence of tumors in which overexpression occurs without amplification, and the association between gene alteration and clinical outcome. A comprehensive study of the gene and its products (RNA and protein) was simultaneously performed on a large number of both tumor types. This analysis identified several potential shortcomings of the various methods used to evaluate HER-2/neu in these diseases (Southern, Northern, and Western blots, and immunohistochemistry) and provided information regarding considerations that should be addressed when studying a gene or gene product in human tissue. The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- {beta}1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
- D. Lesniak, Y. Xu, J. Deschenes, R. Lai, J. Thoms, D. Murray, S. Gosh, J. R. Mackey, S. Sabri, and B. Abdulkarim (2009)
Cancer Res.
69, 8620-8628
| Abstract »
| Full Text »
| PDF »
- Identification of a Sam68 Ribonucleoprotein Complex Regulated by Epidermal Growth Factor.
- M.-E. Huot, G. Vogel, and S. Richard (2009)
J. Biol. Chem.
284, 31903-31913
| Abstract »
| Full Text »
| PDF »
- A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment.
- S. E. Taube, G. M. Clark, J. E. Dancey, L. M. McShane, C. C. Sigman, and S. I. Gutman (2009)
J Natl Cancer Inst
101, 1453-1463
| Abstract »
| Full Text »
| PDF »
- An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
- G. Capri, J. Chang, S.-C. Chen, P. Conte, K. Cwiertka, G. Jerusalem, Z. Jiang, S. Johnston, B. Kaufman, J. Link, et al. (2009)
Ann. Onc.
| Abstract »
| Full Text »
| PDF »
- Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors.
- P. T.P. Kaumaya, K. C. Foy, J. Garrett, S. V. Rawale, D. Vicari, J. M. Thurmond, T. Lamb, A. Mani, Y. Kane, C. R. Balint, et al. (2009)
J. Clin. Oncol.
27, 5270-5277
| Abstract »
| Full Text »
| PDF »
- Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases.
- B. Leyland-Jones (2009)
J. Clin. Oncol.
27, 5278-5286
| Abstract »
| Full Text »
| PDF »
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer.
- D. Zhang, T. A. LaFortune, S. Krishnamurthy, F. J. Esteva, M. Cristofanilli, P. Liu, A. Lucci, B. Singh, M.-C. Hung, G. N. Hortobagyi, et al. (2009)
Clin. Cancer Res.
15, 6639-6648
| Abstract »
| Full Text »
| PDF »
- Reply to E.H. Hammond et al.
- G. Sauter, J. Lee, D. J. Slamon, and M. F. Press (2009)
J. Clin. Oncol.
27, e155-e157
| Full Text »
| PDF »
- Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells.
- F. Reim, Y. Dombrowski, C. Ritter, M. Buttmann, S. Hausler, M. Ossadnik, M. Krockenberger, D. Beier, C. P. Beier, J. Dietl, et al. (2009)
Cancer Res.
69, 8058-8066
| Abstract »
| Full Text »
| PDF »
- Emerging Technologies for Assessing HER2 Amplification.
- F. Penault-Llorca, M. Bilous, M. Dowsett, W. Hanna, R. Y. Osamura, J. Ruschoff, and M. van de Vijver (2009)
Am J Clin Pathol
132, 539-548
| Abstract »
| Full Text »
| PDF »
- OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-{kappa}B pathway and stress response signaling.
- J.-R. Weng, C.-H. Tsai, H. A. Omar, A. M. Sargeant, D. Wang, S. K. Kulp, C. L. Shapiro, and C.-S. Chen (2009)
Carcinogenesis
30, 1702-1709
| Abstract »
| Full Text »
| PDF »
- Optical imaging-guided cancer therapy with fluorescent nanoparticles.
- S. Jiang, M. K. Gnanasammandhan, and Y. Zhang (2009)
J R Soc Interface
| Abstract »
| Full Text »
| PDF »
- A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu.
- P. P. Peethambaram, M. E. Melisko, K. J. Rinn, S. R. Alberts, N. M. Provost, L. A. Jones, R. B. Sims, L. R. C. Lin, M. W. Frohlich, and J. W. Park (2009)
Clin. Cancer Res.
15, 5937-5944
| Abstract »
| Full Text »
| PDF »
- Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity.
- Y. Nagumo, D. Faratian, P. Mullen, D. J. Harrison, M. Hasmann, and S. P. Langdon (2009)
Mol. Cancer Res.
7, 1563-1571
| Abstract »
| Full Text »
| PDF »
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer.
- R. S. Finn, M. F. Press, J. Dering, M. Arbushites, M. Koehler, C. Oliva, L. S. Williams, and A. Di Leo (2009)
J. Clin. Oncol.
27, 3908-3915
| Abstract »
| Full Text »
| PDF »
- Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training.
- M. J. Haykowsky, J. R. Mackey, R. B. Thompson, L. W. Jones, and D. I. Paterson (2009)
Clin. Cancer Res.
15, 4963-4967
| Abstract »
| Full Text »
| PDF »
- HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment.
- J. J. Barron, M. J. Cziraky, T. Weisman, and D. G. Hicks (2009)
Oncologist
14, 760-768
| Abstract »
| Full Text »
| PDF »
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
- Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami (2009)
Ann. Onc.
| Abstract »
| Full Text »
| PDF »
- Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer.
- C. Shah, T. W. Miller, S. K. Wyatt, E. T. McKinley, M. G. Olivares, V. Sanchez, D. D. Nolting, J. R. Buck, P. Zhao, M. S. Ansari, et al. (2009)
Clin. Cancer Res.
15, 4712-4721
| Abstract »
| Full Text »
| PDF »
- Targeted Delivery of Tumor Antigens to Activated Dendritic Cells via CD11c Molecules Induces Potent Antitumor Immunity in Mice.
- H. Wei, S. Wang, D. Zhang, S. Hou, W. Qian, B. Li, H. Guo, G. Kou, J. He, H. Wang, et al. (2009)
Clin. Cancer Res.
15, 4612-4621
| Abstract »
| Full Text »
| PDF »
- Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion.
- T.-H. Huang, F. Wu, G. B. Loeb, R. Hsu, A. Heidersbach, A. Brincat, D. Horiuchi, R. J. Lebbink, Y.-Y. Mo, A. Goga, et al. (2009)
J. Biol. Chem.
284, 18515-18524
| Abstract »
| Full Text »
| PDF »
- Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.
- J. B. Hughes, C. Berger, M. S. Rodland, M. Hasmann, E. Stang, and I. H. Madshus (2009)
Mol. Cancer Ther.
8, 1885-1892
| Abstract »
| Full Text »
| PDF »
- Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial.
- M. Dowsett, M. Procter, W. McCaskill-Stevens, E. de Azambuja, U. Dafni, J. Rueschoff, B. Jordan, S. Dolci, M. Abramovitz, O. Stoss, et al. (2009)
J. Clin. Oncol.
27, 2962-2969
| Abstract »
| Full Text »
| PDF »
- Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia.
- C.-H. Lin, J.-Y. Liau, Y.-S. Lu, C.-S. Huang, W.-C. Lee, K.-T. Kuo, Y.-C. Shen, S.-H. Kuo, C. Lan, J. M. Liu, et al. (2009)
Cancer Epidemiol. Biomarkers Prev.
18, 1807-1814
| Abstract »
| Full Text »
| PDF »
- HER-2/neu analysis in breast cancer bone metastases.
- J Zustin, K Boddin, M C Tsourlakis, E Burandt, M Mirlacher, F Jaenicke, J Izbicki, W Ruether, J M Rueger, C Bokemeyer, et al. (2009)
J. Clin. Pathol.
62, 542-546
| Abstract »
| Full Text »
| PDF »
- Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging.
- E. C.F. Dijkers, J. G.W. Kosterink, A. P. Rademaker, L. R. Perk, G. A.M.S. van Dongen, J. Bart, J. R. de Jong, E. G.E. de Vries, and M. N. Lub-de Hooge (2009)
J. Nucl. Med.
50, 974-981
| Abstract »
| Full Text »
| PDF »
- Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme.
- Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, and H. FUJII (2009)
Anticancer Res
29, 2137-2146
| Abstract »
| Full Text »
| PDF »
- Common Polymorphism in the Phosphatase PHLPP2 Results in Reduced Regulation of Akt and Protein Kinase C.
- J. Brognard, M. Niederst, G. Reyes, N. Warfel, and A. C. Newton (2009)
J. Biol. Chem.
284, 15215-15223
| Abstract »
| Full Text »
| PDF »
- Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers.
- D. J. Slamon and M. F. Press (2009)
J Natl Cancer Inst
101, 615-618
| Full Text »
| PDF »
- Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas.
- K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang (2009)
Cancer Res.
69, 4036-4042
| Abstract »
| Full Text »
| PDF »
- Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma.
- K.-T. Kuo, T.-L. Mao, S. Jones, E. Veras, A. Ayhan, T.-L. Wang, R. Glas, D. Slamon, V. E. Velculescu, R. J. Kuman, et al. (2009)
Am. J. Pathol.
174, 1597-1601
| Abstract »
| Full Text »
| PDF »
- 14-3-3{zeta} Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival.
- C. L. Neal, J. Yao, W. Yang, X. Zhou, N. T. Nguyen, J. Lu, C. G. Danes, H. Guo, K.-H. Lan, J. Ensor, et al. (2009)
Cancer Res.
69, 3425-3432
| Abstract »
| Full Text »
| PDF »
- The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
- L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al. (2009)
Clin. Cancer Res.
15, 2895-2904
| Abstract »
| Full Text »
| PDF »
- Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations.
- Y. Gong, W. Sweet, Y.-J. Duh, L. Greenfield, Y. Fang, J. Zhao, E. Tarco, W. F. Symmans, J. Isola, and N. Sneige (2009)
Am J Clin Pathol
131, 490-497
| Abstract »
| Full Text »
| PDF »
- ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells.
- V. S. Hawthorne, W.-C. Huang, C. L. Neal, L.-M. Tseng, M.-C. Hung, and D. Yu (2009)
Mol. Cancer Res.
7, 592-600
| Abstract »
| Full Text »
| PDF »
- PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas.
- D. S.P. Tan, M. B.K. Lambros, S. Rayter, R. Natrajan, R. Vatcheva, Q. Gao, C. Marchio, F. C. Geyer, K. Savage, S. Parry, et al. (2009)
Clin. Cancer Res.
15, 2269-2280
| Abstract »
| Full Text »
| PDF »
- HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil.
- H. Korkaya and M. S. Wicha (2009)
Clin. Cancer Res.
15, 1845-1847
| Abstract »
| Full Text »
| PDF »
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations.
- G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press (2009)
J. Clin. Oncol.
27, 1323-1333
| Abstract »
| Full Text »
| PDF »
- Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis.
- T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela (2009)
PNAS
106, 3294-3299
| Abstract »
| Full Text »
| PDF »
- Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth.
- C. J. Proietti, C. Rosemblit, W. Beguelin, M. A. Rivas, M. C. Diaz Flaque, E. H. Charreau, R. Schillaci, and P. V. Elizalde (2009)
Mol. Cell. Biol.
29, 1249-1265
| Abstract »
| Full Text »
| PDF »
- Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9.
- L. Aurisicchio, D. Peruzzi, A. Conforti, S. Dharmapuri, A. Biondo, S. Giampaoli, A. Fridman, A. Bagchi, C. T. Winkelmann, R. Gibson, et al. (2009)
Clin. Cancer Res.
15, 1575-1584
| Abstract »
| Full Text »
| PDF »
- Targeted Cancer Therapeutics.
- W. N. Hait and T. W. Hambley (2009)
Cancer Res.
69, 1263-1267
| Abstract »
| Full Text »
| PDF »
- Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas.
- D. Etemadmoghadam, A. deFazio, R. Beroukhim, C. Mermel, J. George, G. Getz, R. Tothill, A. Okamoto, M. B. Raeder, AOCS Study Group, et al. (2009)
Clin. Cancer Res.
15, 1417-1427
| Abstract »
| Full Text »
| PDF »
- Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer.
- J. HORIGUCHI, T. OYAMA, Y. KOIBUCHI, T. YOKOE, D. TAKATA, F. IKEDA, H. NAGAOKA, N. ROKUTANDA, R. NAGAOKA, Y. ISHIKAWA, et al. (2009)
Anticancer Res
29, 517-524
| Abstract »
| Full Text »
| PDF »
- Genetically Targeted T Cells Eradicate Established Breast Cancer in Syngeneic Mice.
- H. Wang, H. Wei, R. Zhang, S. Hou, B. Li, W. Qian, D. Zhang, G. Kou, J. Dai, and Y. Guo (2009)
Clin. Cancer Res.
15, 943-950
| Abstract »
| Full Text »
| PDF »
- Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways.
- L. I. Gordon, M. A. Burke, A. T. K. Singh, S. Prachand, E. D. Lieberman, L. Sun, T. J. Naik, S. V. N. Prasad, and H. Ardehali (2009)
J. Biol. Chem.
284, 2080-2087
| Abstract »
| Full Text »
| PDF »
- Thyroid Hormone Receptor {beta}1 Acts as a Potent Suppressor of Tumor Invasiveness and Metastasis.
- O. Martinez-Iglesias, S. Garcia-Silva, S. P. Tenbaum, J. Regadera, F. Larcher, J. M. Paramio, B. Vennstrom, and A. Aranda (2009)
Cancer Res.
69, 501-509
| Abstract »
| Full Text »
| PDF »
- A Systems Approach to Analysis of Molecular Complexity in Breast Cancer.
- B. T. Hennessy, A. M. Gonzalez-Angulo, M. S. Carey, and G. B. Mills (2009)
Clin. Cancer Res.
15, 417-419
| Abstract »
| Full Text »
| PDF »
- Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort.
- S. Sieri, V. Krogh, G. Bolelli, C. A. Abagnato, S. Grioni, V. Pala, A. Evangelista, C. Allemani, A. Micheli, G. Tagliabue, et al. (2009)
Cancer Epidemiol. Biomarkers Prev.
18, 169-176
| Abstract »
| Full Text »
| PDF »
- Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic Mice.
- O. Radkevich-Brown, J. Jacob, M. Kershaw, and W.-Z. Wei (2009)
Cancer Res.
69, 212-218
| Abstract »
| Full Text »
| PDF »
- Breast lumps and cancer.
- R. Linforth (2009)
InnovAiT
2, 17-23
| Abstract »
| Full Text »
| PDF »
- Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study.
- J. Cortes, S. Di Cosimo, M. A. Climent, H. Cortes-Funes, A. Lluch, P. Gascon, J. I. Mayordomo, M. Gil, M. Benavides, L. Cirera, et al. (2009)
Clin. Cancer Res.
15, 307-314
| Abstract »
| Full Text »
| PDF »
- Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations.
- M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano (2009)
Oncologist
14, 1-11
| Abstract »
| Full Text »
| PDF »
- Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers.
- S. Chia, B. Norris, C. Speers, M. Cheang, B. Gilks, A. M. Gown, D. Huntsman, I. A. Olivotto, T. O. Nielsen, and K. Gelmon (2008)
J. Clin. Oncol.
26, 5697-5704
| Abstract »
| Full Text »
| PDF »
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer.
- A. Di Leo, H. L. Gomez, Z. Aziz, Z. Zvirbule, J. Bines, M. C. Arbushites, S. F. Guerrera, M. Koehler, C. Oliva, S. H. Stein, et al. (2008)
J. Clin. Oncol.
26, 5544-5552
| Abstract »
| Full Text »
| PDF »
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate.
- G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al. (2008)
Cancer Res.
68, 9280-9290
| Abstract »
| Full Text »
| PDF »
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.
- A. Kruschinski, A. Moosmann, I. Poschke, H. Norell, M. Chmielewski, B. Seliger, R. Kiessling, T. Blankenstein, H. Abken, and J. Charo (2008)
PNAS
105, 17481-17486
| Abstract »
| Full Text »
| PDF »
- Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.
- B. Chen, Y. Wang, S. E Kane, and S. Chen (2008)
J. Mol. Endocrinol.
41, 367-377
| Abstract »
| Full Text »
| PDF »
- Luteinizing Hormone-Induced Up-Regulation of ErbB-2 Is Insufficient Stimulant of Growth and Invasion in Ovarian Cancer Cells.
- S. W. Warrenfeltz, S. A. Lott, T. M. Palmer, J. C. Gray, and D. Puett (2008)
Mol. Cancer Res.
6, 1775-1785
| Abstract »
| Full Text »
| PDF »
- Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists.
- A. Carbone, G. Botti, A. Gloghini, G. Simone, M. Truini, M. P. Curcio, P. Gasparini, A. Mangia, T. Perin, S. Salvi, et al. (2008)
J. Mol. Diagn.
10, 527-536
| Abstract »
| Full Text »
| PDF »
- DNA Vaccines Targeting Tumor Antigens to B7 Molecules on Antigen-Presenting Cells Induce Protective Antitumor Immunity and Delay Onset of HER-2/Neu-Driven Mammary Carcinoma.
- A. Sloots, C. Mastini, F. Rohrbach, R. Weth, C. Curcio, U. Burkhardt, E. Jager, G. Forni, F. Cavallo, and W. S. Wels (2008)
Clin. Cancer Res.
14, 6933-6943
| Abstract »
| Full Text »
| PDF »
- Liquid-Based Fluorescence In Situ Hybridization Assay for Detection of ERBB2 Gene Amplification in Patients with Breast Cancer.
- C.-H. Yeh, W. A. Whitmire III, and M. Albitar (2008)
Clin. Chem.
54, 1831-1839
| Abstract »
| Full Text »
| PDF »
- PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation.
- K. Oda, J. Okada, L. Timmerman, P. Rodriguez-Viciana, D. Stokoe, K. Shoji, Y. Taketani, H. Kuramoto, Z. A. Knight, K. M. Shokat, et al. (2008)
Cancer Res.
68, 8127-8136
| Abstract »
| Full Text »
| PDF »
- Studying copy number variations using a nanofluidic platform.
- J. Qin, R. C. Jones, and R. Ramakrishnan (2008)
Nucleic Acids Res.
36, e116
| Abstract »
| Full Text »
| PDF »
- Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer.
- M. Barve, J. Bender, N. Senzer, C. Cunningham, F. A. Greco, D. McCune, R. Steis, H. Khong, D. Richards, J. Stephenson, et al. (2008)
J. Clin. Oncol.
26, 4418-4425
| Abstract »
| Full Text »
| PDF »
- Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts.
- C. J. Creighton, S. Massarweh, S. Huang, A. Tsimelzon, S. G. Hilsenbeck, C. K. Osborne, J. Shou, L. Malorni, and R. Schiff (2008)
Cancer Res.
68, 7493-7501
| Abstract »
| Full Text »
| PDF »
- DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted Therapies.
- P. J. Whittington, M. P. Piechocki, H. H. Heng, J. B. Jacob, R. F. Jones, J. B. Back, and W.-Z. Wei (2008)
Cancer Res.
68, 7502-7511
| Abstract »
| Full Text »
| PDF »
- A Cautionary Note on the Evaluation of Biomarkers of Subtypes of a Single Disease.
- A. J. Adewale, Q. Liu, I. Dinu, P. D. Lampe, B. L. Mitchell, and Y. Yasui (2008)
Am. J. Epidemiol.
168, 559-562
| Abstract »
| Full Text »
| PDF »
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.
- C. Gravalos and A. Jimeno (2008)
Ann. Onc.
19, 1523-1529
| Abstract »
| Full Text »
| PDF »
- Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
- D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter (2008)
Ann. Onc.
19, 1530-1539
| Abstract »
| Full Text »
| PDF »
- HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
- P. Haluska, J. M. Carboni, C. TenEyck, R. M. Attar, X. Hou, C. Yu, M. Sagar, T. W. Wong, M. M. Gottardis, and C. Erlichman (2008)
Mol. Cancer Ther.
7, 2589-2598
| Abstract »
| Full Text »
| PDF »
- Brk is coamplified with ErbB2 to promote proliferation in breast cancer.
- B. Xiang, K. Chatti, H. Qiu, B. Lakshmi, A. Krasnitz, J. Hicks, M. Yu, W. T. Miller, and S. K. Muthuswamy (2008)
PNAS
105, 12463-12468
| Abstract »
| Full Text »
| PDF »
- Chromosomal Abnormalities in Cancer.
- S. Frohling and H. Dohner (2008)
N. Engl. J. Med.
359, 722-734
| Full Text »
| PDF »
- Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells.
- M. Lombardi, G. Castoria, A. Migliaccio, M. V. Barone, R. Di Stasio, A. Ciociola, D. Bottero, H. Yamaguchi, E. Appella, and F. Auricchio (2008)
J. Cell Biol.
182, 327-340
| Abstract »
| Full Text »
| PDF »
- Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine.
- J. P. Holmes, L. C. Benavides, J. D. Gates, M. G. Carmichael, M. T. Hueman, E. A. Mittendorf, J. L. Murray, A. Amin, D. Craig, E. von Hofe, et al. (2008)
J. Clin. Oncol.
26, 3426-3433
| Abstract »
| Full Text »
| PDF »
- Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties.
- A. D. Gritzapis, I. F. Voutsas, E. Lekka, N. Tsavaris, I. Missitzis, P. Sotiropoulou, S. Perez, M. Papamichail, and C. N. Baxevanis (2008)
J. Immunol.
181, 146-154
| Abstract »
| Full Text »
| PDF »
- Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
- D. Zhang, A. Pal, W. G. Bornmann, F. Yamasaki, F. J. Esteva, G. N. Hortobagyi, C. Bartholomeusz, and N. T. Ueno (2008)
Mol. Cancer Ther.
7, 1846-1850
| Abstract »
| Full Text »
| PDF »
- Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth.
- X.-C. Qiu, Y.-M. Xu, F. Wang, Q.-Y. Fan, L.-F. Wang, B.-A. Ma, L.-T. Jia, J. Zhao, Y.-L. Meng, L.-B. Yao, et al. (2008)
Mol. Cancer Ther.
7, 1890-1899
| Abstract »
| Full Text »
| PDF »
- Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer.
- H. L. Gomez, D. C. Doval, M. A. Chavez, P. C.-S. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W.C. Chow, M. C. Arbushites, et al. (2008)
J. Clin. Oncol.
26, 2999-3005
| Abstract »
| Full Text »
| PDF »
- Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- I. J. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, and S. Murray (2008)
Oncologist
13, 620-630
| Abstract »
| Full Text »
| PDF »
- Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPAR{beta}/{delta} to RAR.
- T. T. Schug, D. C. Berry, I. A. Toshkov, L. Cheng, A. Y. Nikitin, and N. Noy (2008)
PNAS
105, 7546-7551
| Abstract »
| Full Text »
| PDF »
- Signaling through ShcA Is Required for Transforming Growth Factor {beta}- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion.
- J. J. Northey, J. Chmielecki, E. Ngan, C. Russo, M. G. Annis, W. J. Muller, and P. M. Siegel (2008)
Mol. Cell. Biol.
28, 3162-3176
| Abstract »
| Full Text »
| PDF »
- The Fibroblast Growth Factor-Inducible 14 Receptor Is Highly Expressed in HER2-Positive Breast Tumors and Regulates Breast Cancer Cell Invasive Capacity.
- A. L. Willis, N. L. Tran, J. M. Chatigny, N. Charlton, H. Vu, S. A.N. Brown, M. A. Black, W. S. McDonough, S. P. Fortin, J. R. Niska, et al. (2008)
Mol. Cancer Res.
6, 725-734
| Abstract »
| Full Text »
| PDF »
- t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways.
- X. Meng, S. F. Shoemaker, S. O. McGee, and M. M. Ip (2008)
Carcinogenesis
29, 1013-1021
| Abstract »
| Full Text »
| PDF »
- Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer.
- A. Jimeno, A. C. Tan, J. Coffa, N.V. Rajeshkumar, P. Kulesza, B. Rubio-Viqueira, J. Wheelhouse, B. Diosdado, W. A. Messersmith, C. Iacobuzio-Donahue, et al. (2008)
Cancer Res.
68, 2841-2849
| Abstract »
| Full Text »
| PDF »
- Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis.
- N. Dourdin, B. Schade, R. Lesurf, M. Hallett, R. J. Munn, R. D. Cardiff, and W. J. Muller (2008)
Cancer Res.
68, 2122-2131
| Abstract »
| Full Text »
| PDF »
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance.
- G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff (2008)
Endocr. Rev.
29, 217-233
| Abstract »
| Full Text »
| PDF »
- Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
- K.-K. Kim, J. J. Lee, Y. Yang, K.-H. You, and J.-H. Lee (2008)
Carcinogenesis
29, 704-712
| Abstract »
| Full Text »
| PDF »
- Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
- R. A. Lubet, E. Szabo, K. Christov, A. M. Bode, M. E. Ericson, V. E. Steele, M. M. Juliana, and C. J. Grubbs (2008)
Mol. Cancer Ther.
7, 972-979
| Abstract »
| Full Text »
| PDF »
|
|